Long-term outcomes of the observe-and-plan regimen in treating neovascular age-related macular degeneration: a retrospective real-life analysis

• Published in: Eye (London) Vol. 39; no. 11; pp. 2188 - 2193
• Main Authors: Sherif, M., Derradji, Y., Safi, A., Mantel, I.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.08.2025; Nature Publishing Group
• Subjects: 13/1; 692/699; 692/699/3161; Acuity; Age; Aged; Aged, 80 and over; Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - therapeutic use; Diabetes; Diabetes mellitus; Diabetic retinopathy; Female; Follow-Up Studies; Humans; Intravitreal Injections; Laboratory Medicine; Macular degeneration; Male; Medical imaging; Medicine; Medicine & Public Health; Ophthalmology; Patients; Pharmaceutical Sciences/Technology; Photodynamic therapy; Ranibizumab - administration & dosage; Ranibizumab - therapeutic use; Receptors, Vascular Endothelial Growth Factor - administration & dosage; Receptors, Vascular Endothelial Growth Factor - therapeutic use; Recombinant Fusion Proteins - administration & dosage; Recombinant Fusion Proteins - therapeutic use; Retinopathy; Retrospective Studies; Structure-function relationships; Surgery; Surgical Oncology; Tomography, Optical Coherence; Treatment Outcome; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual acuity; Visual Acuity - physiology; Wet Macular Degeneration - diagnosis; Wet Macular Degeneration - drug therapy; Wet Macular Degeneration - physiopathology; Germany
• ISSN: 0950-222X; 1476-5454; 1476-5454
• DOI: 10.1038/s41433-025-03830-1

Background/Objectives This study aimed to evaluate the long-term (7 years) outcome of visual acuity in patients with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (VEGF) agents following the observe-and-plan regimen. Subjects/Methods A total...